Phase 2 × Terminated × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Clear all
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT00057954 2023-06-28

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Terminated
6 enrolled 7 charts
NCT01028716 2023-01-23

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 2 Terminated
46 enrolled 18 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT01419795 2017-07-27

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
NCT00818961 2013-12-18

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
36 enrolled 16 charts
NCT00827099 2012-03-23

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
5 enrolled 5 charts